What we are studying
This research study is being done to see if, and how well, your type of cancer responds to the investigational drug called LOXO-101. You must have an alteration (change) in a particular gene called NTRK1, NTRK2 or NTRK3 within your cancer in order to participate in this study. LOXO-101 is an oral investigational (or experimental) drug that blocks the actions of the NTRK genes in cancer cells and may be useful to treat cancer. In this study, LOXO-101 will be studied in 8 different groups of subjects (called cohorts) determined by cancer type.
Type of Cancer: Non-small Cell Lung, Thyroid, Sarcoma, Colon (Colorectal), Salivary, Biliary, Primary CNS, Other Solid Tumors
Travel expenses may be reimbursed. A travel service will also be made available to you and a companion caregiver if needed. This service is offered to you to reduce your out-of-pocket expenses.